Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing innovative medicines to improve the lives of cancer patients. The company's drug candidates include ripretinib, a broad-spectrum KIT and PDGFR? inhibitor, and DCC-3014, a selective inhibitor of CSF1R. Ripretinib is in clinical development for the treatment of gastrointestinal stromal tumors (GIST), systemic mastocytosis (SM), and other solid tumors. DCC-3014 is in Phase 1 clinical development for the treatment of solid tumors. Deciphera Pharmaceuticals is headquartered in Waltham, Massachusetts.